Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?
Gilberto Lopes/ LinkedIn

Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?

Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared on LinkedIn:

“Ivonescimab, the FDA, and a difficult question in oncology: When is progression-free survival enough?

On November 13, FDA declined approval of ivonescimab plus chemotherapy for EGFR-mutated NSCLC after EGFR TKI treatment.

In global HARMONi, median PFS improved from 4.4 to 6.8 months (HR 0.52). OS favored ivonescimab (16.8 vs 14.0 months; HR 0.79), but did not meet prespecified statistical significance (P=.057). Longer follow-up suggested an OS HR of 0.76, but this was exploratory and cannot replace the primary analysis.

There is a historical precedent. VEGF inhibition with bevacizumab improved PFS without statistically significant OS benefits in metastatic breast cancer, ovarian cancer, and the AVAiL NSCLC trial. This was not universal: ECOG 4599 found significant PFS and OS improvements.

PFS can matter to patients, but its relationship to OS varies with the disease, subsequent therapy, treatment toxicity and other clinical factors.

The ivonescimab story is also evolving. Randomized phase III studies in China have demonstrated statistically significant OS benefits in other settings: HARMONi-A after EGFR TKI therapy (HR 0.74); HARMONi-2 in first-line PD-L1-positive NSCLC versus pembrolizumab (HR 0.73); and HARMONi-6 in first-line squamous NSCLC versus tislelizumab plus chemotherapy (HR 0.66).

These results strengthen confidence in dual PD-1/VEGF inhibition, but do not resolve the global HARMONi application. HARMONi-A and global HARMONi also have overlapping patient origins.

FDA raised additional concerns about geographic generalizability, the predominance of progression events in Chinese participants, exploratory survival analyses, and benefit–risk given added toxicity.

A 48% relative reduction in the hazard of progression or death is an important result in a population with substantial unmet need. But magnitude of benefit, statistical reliability, representativeness, symptoms, quality of life and toxicity all matter.

Having worked in thoracic oncology and drug development across Asia, North America, and Latin America, I appreciate the different perspectives on this question. We need prespecified analyses and rigorous, representative trials. At the same time, OS is not the only potentially meaningful endpoint, particularly when PFS is accompanied by better symptoms, function or quality of life.

A drug can be promising without having met the evidentiary requirements for approval. A regulatory rejection does not necessarily mean it lacks clinical value.

The ivonescimab story is far from over. Science advances when we remain open to new evidence while holding it to rigorous standards.

Sources: FDA CRL (Nov 13, 2026); HARMONi program; ECOG 4599, AVAiL, E2100, GOG-0218 and ICON7.”

Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?